Charles River Laboratories International, Inc.
CRLNYSEHealthcareDiagnostics & Research

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It utilizes Logica, a platform offering from Valo Health, to identify advanceable small molecule leads. It provides contract vivarium operation services to biopharmaceutical clients. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children’s Hospital Los Angeles across its contract development and manufacturing organization. Additionally, It has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Company Information

CEOJames Foster
Founded1947
IPO DateJune 23, 2000
Employees20,100
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSE (NYSE)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone781 222 6000
Address
251 Ballardvale Street Wilmington, Massachusetts 01887 United States

Corporate Identifiers

CIK0001100682
CUSIP159864107
ISINUS1598641074
EIN06-1397316
SIC8731

Leadership Team & Key Executives

James C. Foster J.D.
Chairman, President and Chief Executive Officer
Birgit Girshick
Corporate Executive Vice President and Chief Operating Officer
Joseph W. LaPlume J.D.
Corporate Executive Vice President of Corporate Development and Strategy
Victoria L. Creamer
Corporate Executive Vice President and Chief People Officer
Michael Gunnar Knell
Interim Chief Financial Officer, Corporate Senior Vice President and Chief Accounting Officer
Prof. Julie Frearson Ph.D.
Corporate Senior Vice President and Chief Scientific Officer
Mark Mintz
Corporate EVice President, Chief Information Officer and Global Shared Services
Todd Spencer
Corporate Vice President of Investor Relations
Matthew L. Daniel J.D.
Corporate Senior Vice President, General Counsel, Corporate Secretary and Chief Compliance Officer
Amy E. Cianciaruso
Corporate Senior Vice President, Chief Communications Officer and Government Relations